Immunogenicity and Efficacy of Personalized Adjuvant mRNA Cancer Vaccines
Pedro Berraondo, Raquel Cuesta, Miguel F. Sanmamed, Ignacio Melero
Abstract
In this issue, Gainor and colleagues report on the immunogenicity of personalized neoantigen-encoding mRNA vaccines that elicit measurable polyfunctional CD8+ and CD4+ T-cell responses in patients whose tumors have been resected. Reactivity is substantiated to 20% to 30% of the predicted MHC-I and MHC-II epitopes in four patients with NSCLC postsurgically treated with the vaccine alone and in 12 patients with melanoma treated with their individualized vaccines plus pembrolizumab in the context of a phase 1 clinical trial (NCT03313778). See related article by Gainor et al., p. 2209.
Topics & Concepts
ImmunogenicityPembrolizumabContext (archaeology)AdjuvantEpitopeMedicineImmunologyCancer vaccineMajor histocompatibility complexMHC class ICancerImmunotherapyCancer immunotherapyCD8VirologyImmune systemAntigenBiologyInternal medicinePaleontologyImmunotherapy and Immune ResponsesCancer Immunotherapy and BiomarkersCAR-T cell therapy research